AG014699, the phosphate salt of AG14447, which has improved aqueous solubility, has been selected for clinical trial.AG014699 is a tricyclic indole poly(ADP-Ribose) polymerase (PARP) inhibitor with potential antineoplastic activity.
CAS No: 459868-92-9
Rucaparib, PF-01367338283173-50-2 cas 6H-Pyrrolo[4,3,2-ef]benzazepin-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H- Azepino[5,4,3-cd]indol-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl] -8-Fluoro-2-[4-[(methylamino)methyl]phenyl]-1,3,4,5- tetrahydro-6H-azepino[5,4,3-cd]indol-6-one;8-Fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one8-Fluoro-2-(4-methylaminomethyl-phenyI)-l,3,4,5-tetrahydro-azepino[5,4,3- cd]indol-6-one
- MW..C19 H18 F N3 O
- cas of csa salt—–1327258-57-0
- 773059-19-1 (hydrochloride)
- 459868-92-9 PHOSPHATE
AG-014447 (free base)
AG-14447 (free base)
- Agouron (Originator)
- Clovis Oncology
- WO 2014052550, WO 2014037313, WO 2000042040WO 2004087713WO 2005012305
Rucaparib (AG 014699) is a PARP inhibitor being investigated as a potential anti-cancer agent.
Rucaparib inhibits “the contraction of isolated vascular smooth muscle, including that from the tumours of cancer patients. It also reduces the migration of some cancer and normal cells in culture.”
It can be taken orally in tablet form.
View original post 1,817 more words